Clinical, Molecular, and Prognostic Comparisons Between CCUS and Lower-risk MDS: a Study of 187 Molecularly Annotated Patients

Overview

Journal Blood Adv

Specialty Hematology

Date 2021 Apr 27

PMID 33904893

Citations 14

Authors

Marissa Li

Moritz Binder

Terra Lasho

Alejandro Ferrer

Naseema Gangat

Aref Al-Kali

Abhishek Mangaonkar

Michelle Elliott

Mark Litzow

William Hogan

Animesh Pardanani

Alexandra Wolanskyj-Spinner

Matthew Howard

Rebecca L King

Mithun Shah

Hassan Alkhateeb

Kebede Begna

Ayalew Tefferi

Christy Finke

Jennifer Oliveira

Rhett Ketterling

Horatiu Olteanu

Mrinal M Patnaik

Affiliations

Soon will be listed here.

Citing Articles

Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.

Zhang Q, Yim R, Lee P, Chin L, Li V, Gill H Cancers (Basel). 2024; 16(23).

PMID: 39682303 PMC: 11640442. DOI: 10.3390/cancers16234118.

A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.

Haque T, Shastri A, Desai P, Xie Z, Hammond D, King Z Br J Haematol. 2024; 206(2):416-427.

PMID: 39653653 PMC: 11829135. DOI: 10.1111/bjh.19925.

Can molecular patterns help to classify overlapping entities in myeloid neoplasms?.

Hoermann G, Khoury J Histopathology. 2024; 86(1):146-157.

PMID: 39428913 PMC: 11648353. DOI: 10.1111/his.15339.

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.

Xie Z, Fernandez J, Lasho T, Finke C, Amundson M, McCullough K Blood. 2024; 144(23):2456-2461.

PMID: 39352751 PMC: 11628862. DOI: 10.1182/blood.2024024962.

Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.

Nathan D, Brander T, Gold J, Paul D, Klein P, Cheng K JCO Precis Oncol. 2024; 8:e2400006.

PMID: 38991177 PMC: 11285011. DOI: 10.1200/PO.24.00006.

References

Cazzola M . Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374. DOI: 10.1056/NEJMra1904794. View

Makishima H, Yoshizato T, Yoshida K, Sekeres M, Radivoyevitch T, Suzuki H . Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2016; 49(2):204-212. PMC: 8210656. DOI: 10.1038/ng.3742. View

Austin P, Fine J . Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017; 36(27):4391-4400. PMC: 5698744. DOI: 10.1002/sim.7501. View

Patnaik M, Lasho T, Hodnefield J, Knudson R, Ketterling R, Garcia-Manero G . SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2011; 119(2):569-72. PMC: 4916563. DOI: 10.1182/blood-2011-09-377994. View

Mangaonkar A, Ferrer A, Pinto E Vairo F, Cousin M, Kuisle R, Gangat N . Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clin Proc. 2019; 94(9):1753-1768. PMC: 6728219. DOI: 10.1016/j.mayocp.2019.04.007. View

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

Patnaik M, Itzykson R, Lasho T, Kosmider O, Finke C, Hanson C . ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014; 28(11):2206-12. DOI: 10.1038/leu.2014.125. View

Jaiswal S, Natarajan P, Silver A, Gibson C, Bick A, Shvartz E . Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017; 377(2):111-121. PMC: 6717509. DOI: 10.1056/NEJMoa1701719. View

Patnaik M, Lasho T . Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):460-464. PMC: 7727594. DOI: 10.1182/hematology.2020000163. View

10.

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

11.

Malcovati L, Galli A, Travaglino E, Ambaglio I, Rizzo E, Molteni E . Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017; 129(25):3371-3378. PMC: 5542849. DOI: 10.1182/blood-2017-01-763425. View

12.

. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. Blood. 2019; 128(3):462-463. DOI: 10.1182/blood-2016-06-721662. View

13.

Platzbecker U, Fenaux P, Ades L, Giagounidis A, Santini V, van de Loosdrecht A . Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2018; 133(10):1020-1030. PMC: 7042664. DOI: 10.1182/blood-2018-06-857102. View

14.

Gondek L, DeZern A . Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematol. 2019; 7(1):e73-e81. PMC: 7008978. DOI: 10.1016/S2352-3026(19)30211-X. View